2023
Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial
Dicko A, Ouedraogo J, Zongo I, Sagara I, Cairns M, Yerbanga R, Issiaka D, Zoungrana C, Sidibe Y, Tapily A, Nikièma F, Sompougdou F, Sanogo K, Kaya M, Yalcouye H, Dicko O, Diarra M, Diarra K, Thera I, Haro A, Sienou A, Traore S, Mahamar A, Dolo A, Kuepfer I, Snell P, Grant J, Webster J, Milligan P, Lee C, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Chandramohan D, Greenwood B. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. The Lancet Infectious Diseases 2023, 24: 75-86. PMID: 37625434, DOI: 10.1016/s1473-3099(23)00368-7.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionPhase 3 trialClinical malariaAlone groupMalaria Vaccine InitiativeMalaria chemopreventionSeasonal vaccinationProtective efficacyCombined groupPATH Malaria Vaccine InitiativeGlobal Health TrialsPrimary trial endpointSeasonal malaria transmissionSingle intervention groupSupplementary Materials sectionBougouni DistrictCause deathModified intentionProtocol populationControl vaccineMalaria vaccinationMalarial anemiaSevere malariaBlood transfusionHospital admissionSeasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study
Roh M, Zongo I, Haro A, Huang L, Somé A, Yerbanga R, Conrad M, Wallender E, Legac J, Aweeka F, Ouédraogo J, Rosenthal P. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. The Journal Of Infectious Diseases 2023, 228: 926-935. PMID: 37221018, PMCID: PMC10547452, DOI: 10.1093/infdis/jiad172.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDrug levelsMonths of ageOdds ratioHigh-level SP resistanceSP-AQCase-control studyConditional logistic regressionLow drug levelsPrevalence of mutationsDrug resistance markersCase-control designResistance markersIncident malariaParasitemic childrenMalaria chemopreventionAntimalarial resistanceChildren 6Health facilitiesSP resistanceChildren 3Malaria incidenceDrug resistanceMalariaLogistic regressionCost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso
Diawara H, Bocoum F, Dicko A, Levin A, Lee C, Koita F, Ouédraogo J, Guissou R, Yabré S, Traoré S, Morgan W, Pecenka C, Baral R. Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso. BMJ Global Health 2023, 8: e011316. PMID: 37068848, PMCID: PMC10111920, DOI: 10.1136/bmjgh-2022-011316.Peer-Reviewed Original ResearchConceptsVaccine deliverySeasonal vaccinationMalaria vaccineMalaria transmissionSeasonal malaria transmissionRoutine Expanded ProgrammeResource use dataRoutine EPINew vaccine introductionSeasonal malariaVaccine introductionMain cost driversHealth facilitiesExpanded ProgrammeVaccine priceVaccine rolloutMass campaignsService deliveryYoung childrenVaccinationCost consequencesBurkina FasoFinancial costsVaccineDelivery approach
2022
Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study
Thompson H, Hogan A, Walker P, Winskill P, Zongo I, Sagara I, Tinto H, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B, Cairns M, Ghani A. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study. The Lancet Global Health 2022, 10: e1782-e1792. PMID: 36400084, DOI: 10.1016/s2214-109x(22)00416-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionSeasonal transmission settingsS vaccinationTransmission settingsTransmission seasonFull therapeutic coursePhase 3b trialSevere malaria outcomesUK Medical Research CouncilEstimates of casesDuration of protectionMalaria transmission intensityEntomological inoculation rateGreater absolute reductionMedical Research CouncilTransmission intensitySignificant additional protectionAge-based strategiesMalaria outcomesClinical malariaMalaria chemopreventionVaccination scheduleMalaria vaccineClinical incidenceClinical trialsPreventive small-quantity lipid-based nutrient supplements reduce severe wasting and severe stunting among young children: an individual participant data meta-analysis of randomized controlled trials
Dewey K, Arnold C, Wessells K, Prado E, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold B, Ashorn P, Ashorn U, Ashraf S, Becquey E, Brown K, Christian P, Colford J, Dulience S, Fernald L, Galasso E, Hallamaa L, Hess S, Humphrey J, Huybregts L, Iannotti L, Jannat K, Lartey A, Le Port A, Leroy J, Luby S, Maleta K, Matias S, Mbuya M, Mridha M, Nkhoma M, Null C, Paul R, Okronipa H, Ouédraogo J, Pickering A, Prendergast A, Ruel M, Shaikh S, Weber A, Wolff P, Zongrone A, Stewart C. Preventive small-quantity lipid-based nutrient supplements reduce severe wasting and severe stunting among young children: an individual participant data meta-analysis of randomized controlled trials. American Journal Of Clinical Nutrition 2022, 116: 1314-1333. PMID: 36045000, DOI: 10.1093/ajcn/nqac232.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsLipid-based nutrient supplementsSevere wastingIndividual participant dataParticipant dataPassive control armStudy-level characteristicsSevere stuntingMo of ageFixed-effects modelNutrient supplementsHealthy child growthControl armChildren 6Inclusion criteriaEffect modifiersPreventive interventionsChild wastingGreater burdenSubgroup estimatesWastingChild growthYoung childrenStuntingRelative reductionPrevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study
Beshir K, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K, Ceesay S, Bazie T, Kolie F, Lamine M, Cairns M, Snell P, Scott S, Diallo A, Merle C, NDiaye J, Razafindralambo L, Moroso D, Ouedraogo J, Zongo I, Kessely H, Doumagoum D, Bojang K, Ceesay S, Loua K, Maiga H, Dicko A, Sagara I, Laminou I, Ogboi S, Eloike T, Milligan P, Sutherland C. Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. The Lancet Infectious Diseases 2022, 23: 361-370. PMID: 36328000, DOI: 10.1016/s1473-3099(22)00593-x.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionResistance-associated variantsParasite carriageSurvey-weighted prevalenceMalaria transmission seasonQuantitative PCRPrevalence ratiosP falciparumGenomic surveillance studyChemoprevention drugsBlood samplesSurveillance studyTransmission seasonChemopreventionPlasmodium falciparumAmodiaquinePrevalenceMDR1Variant haplotypeSequencing of isolatesSignificant reductionChildrenPyrimethamineCommunity surveyEthical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M, Dondorp A, Amaratunga C, Mokuolu O, Ouedraogo J, Cheah P. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLOS ONE 2022, 17: e0273249. PMID: 36083995, PMCID: PMC9462557, DOI: 10.1371/journal.pone.0273249.Peer-Reviewed Original ResearchConceptsTriple artemisinin-based combination therapiesArtemisinin-based combination therapyCombination therapyArtemisinin resistanceUncomplicated Plasmodium falciparum malariaDrug resistancePlasmodium falciparum malariaMalaria-endemic countriesPartner drug resistanceAdditional side effectsUncomplicated malariaFalciparum malariaTreatment optionsEndemic countriesPediatric diseasesSide effectsACT failureMalariaTherapyBurkina FasoFocus group discussionsEthical considerationsTreatmentQualitative studyStakeholder engagement activitiesSmall-quantity lipid-based nutrient supplements, with or without added zinc, do not cause excessive fat deposition in Burkinabe children: results from a cluster-randomized community trial
Abbeddou S, Jimenez E, Hess S, Somé J, Ouédraogo J, Brown K. Small-quantity lipid-based nutrient supplements, with or without added zinc, do not cause excessive fat deposition in Burkinabe children: results from a cluster-randomized community trial. European Journal Of Nutrition 2022, 61: 4107-4120. PMID: 35829783, PMCID: PMC9596589, DOI: 10.1007/s00394-022-02936-6.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsNon-intervention cohortLipid-based nutrient supplementsIntervention cohortIntervention groupCluster-randomized community trialFat-free mass accretionAdditional zinc supplementationFat depositionTrial registrationThe studyCluster-randomized trial designDispersible tabletsMonths of ageExcessive fat depositionMorbidity treatmentNIC childrenNutrient supplementsBurkinabe childrenUS National InstitutesObesity riskZinc supplementationClinical trialsCommunity trialFat massTrial designTemporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis
Dahal P, Simpson J, Abdulla S, Achan J, Adam I, Agarwal A, Allan R, Anvikar A, Arinaitwe E, Ashley E, Awab G, Bassat Q, Björkman A, Borrmann S, Bousema T, Bukirwa H, Carrara V, Corsi M, Cot M, D’Alessandro U, Davis T, Deloron P, Desai M, Dimbu P, Djalle D, Djimde A, Dorsey G, Drakeley C, Duparc S, Edstein M, Espie E, Faiz A, Falade C, Fanello C, Faucher J, Faye B, de Jesus Fortes F, Gadalla N, Gaye O, Gil J, Gilayeneh J, Greenwood B, Grivoyannis A, Hien T, Hwang J, Janssens B, Juma E, Kamugisha E, Karema C, Karunajeewa H, Kiechel J, Kironde F, Kofoed P, Kremsner P, Lee S, Marsh K, Mårtensson A, Mayxay M, Menan H, Mens P, Mutabingwa T, Ndiaye J, Ngasala B, Noedl H, Nosten F, Offianan A, Ogutu B, Olliaro P, Ouedraogo J, Piola P, Plowe C, Plucinski M, Pratt O, Premji Z, Ramharter M, Rogier C, Rombo L, Rosenthal P, Sibley C, Sirima S, Smithuis F, Staedke S, Sutanto I, Talisuna A, Tarning J, Taylor W, Temu E, Thriemer K, Thuy-Nhien N, Udhayakumar V, Ursing J, van Herp M, van Lenthe M, van Vugt M, William Y, Winnips C, Zaloumis S, Zongo I, White N, Guerin P, Stepniewska K, Price R. Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal 2022, 21: 106. PMID: 35331243, PMCID: PMC8943927, DOI: 10.1186/s12936-021-03980-z.Peer-Reviewed Original ResearchConceptsDihydroartemisinin-piperaquineDays follow-upFollow-upEfficacy trialsRecrudescent infectionsRisk of recrudescenceAnti-malarial efficacy studiesUncomplicated Plasmodium falciparum malariaArtemisinin-based combination therapyDuration of follow-upPlasmodium falciparum malariaAnti-malarial treatmentMethodsIndividual patient dataFollow-up periodFollow-up time pointsCox regression modelsClinical efficacy trialsTreatment Efficacy TrialData meta-analysisTrial follow-upMalaria recrudescencePiperaquine dosingRecrudescent parasitaemiaFalciparum malariaOptimal follow-up periodDelivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study
Ward C, Phillips A, Oresanya O, Olisenekwu G, Arogunade E, Moukénet A, Beakgoubé H, De Paul Allambademel V, Compaoré C, Traoré A, Ouedraogo J, Compaoré Y, Zongo I, Donovan L, Decola M, Smith H, Baker K. Delivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study. Malaria Journal 2022, 21: 103. PMID: 35331248, PMCID: PMC8943494, DOI: 10.1186/s12936-022-04091-z.Peer-Reviewed Original ResearchConceptsCross-sectional studyIPC measuresMalaria chemopreventionInfection preventionMethodsA cross-sectional studyEnhanced infection preventionSeasonal malaria chemopreventionCoronavirus disease 2019 (COVID-19) transmissionHigh malaria transmissionOptimal hand hygiene practicesHand hygiene practicesProportion of indicationsCOVID-19 pandemicEarly community engagementFirst doseHand hygieneWHO guidanceMalaria transmissionBurkina FasoHand washingControl measuresHygiene practicesProtective equipmentAdherenceBlister packsHaematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data
Mansoor R, Commons R, Douglas N, Abuaku B, Achan J, Adam I, Adjei G, Adjuik M, Alemayehu B, Allan R, Allen E, Anvikar A, Arinaitwe E, Ashley E, Ashurst H, Asih P, Bakyaita N, Barennes H, Barnes K, Basco L, Bassat Q, Baudin E, Bell D, Bethell D, Bjorkman A, Boulton C, Bousema T, Brasseur P, Bukirwa H, Burrow R, Carrara V, Cot M, D’Alessandro U, Das D, Das S, Davis T, Desai M, Djimde A, Dondorp A, Dorsey G, Drakeley C, Duparc S, Espié E, Etard J, Falade C, Faucher J, Filler S, Fogg C, Fukuda M, Gaye O, Genton B, Rahim A, Gilayeneh J, Gonzalez R, Grais R, Grandesso F, Greenwood B, Grivoyannis A, Hatz C, Hodel E, Humphreys G, Hwang J, Ishengoma D, Juma E, Kachur S, Kager P, Kamugisha E, Kamya M, Karema C, Kayentao K, Kazienga A, Kiechel J, Kofoed P, Koram K, Kremsner P, Lalloo D, Laman M, Lee S, Lell B, Maiga A, Mårtensson A, Mayxay M, Mbacham W, McGready R, Menan H, Ménard D, Mockenhaupt F, Moore B, Müller O, Nahum A, Ndiaye J, Newton P, Ngasala B, Nikiema F, Nji A, Noedl H, Nosten F, Ogutu B, Ojurongbe O, Osorio L, Ouédraogo J, Owusu-Agyei S, Pareek A, Penali L, Piola P, Plucinski M, Premji Z, Ramharter M, Richmond C, Rombo L, Roper C, Rosenthal P, Salman S, Same-Ekobo A, Sibley C, Sirima S, Smithuis F, Somé F, Staedke S, Starzengruber P, Strub-Wourgaft N, Sutanto I, Swarthout T, Syafruddin D, Talisuna A, Taylor W, Temu E, Thwing J, Tinto H, Tjitra E, Touré O, Tran T, Ursing J, Valea I, Valentini G, van Vugt M, von Seidlein L, Ward S, Were V, White N, Woodrow C, Yavo W, Yeka A, Zongo I, Simpson J, Guerin P, Stepniewska K, Price R. Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine 2022, 20: 85. PMID: 35249546, PMCID: PMC8900374, DOI: 10.1186/s12916-022-02265-9.Peer-Reviewed Original ResearchConceptsUncomplicated P. falciparum malariaSevere anemiaDay 7Nadir hemoglobinParasite clearanceTreatment of uncomplicated P. falciparum malariaDay 3Risk factorsHaematological responseRate of parasite clearanceWorldWide Antimalarial Resistance NetworkArtemisinin-based regimensBackgroundPlasmodium falciparum malariaDelayed parasite clearanceMethodsIndividual patient dataMedian hemoglobin concentrationIndependent risk factorRisk of anemiaArtemisinin-based treatmentsDay 2 post treatmentDay of nadirModerately severe anemiaIndividual patient dataPatient dataMalarial anemiaImpact of seasonal RTS,S/AS01E vaccination plus seasonal malaria chemoprevention on the nutritional status of children in Burkina Faso and Mali
Grant J, Sagara I, Zongo I, Cairns M, Yerbanga R, Diarra M, Zoungrana C, Issiaka D, Nikièma F, Sompougdou F, Tapily A, Kaya M, Haro A, Sanogo K, Sienou A, Traore S, Thera I, Yalcouye H, Kuepfer I, Snell P, Milligan P, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Chandramohan D, Greenwood B, Dicko A, Ouédraogo J. Impact of seasonal RTS,S/AS01E vaccination plus seasonal malaria chemoprevention on the nutritional status of children in Burkina Faso and Mali. Malaria Journal 2022, 21: 59. PMID: 35193608, PMCID: PMC8864823, DOI: 10.1186/s12936-022-04077-x.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionSevere wastingHigh burdenTransmission seasonCombined groupNutritional statusMalaria transmission seasonNutritional status indicatorsPrevalence of stuntingIncidence of malariaCross-sectional surveyMalaria vaccinationSevere malariaRecent trialsStudy populationAS01ELow prevalenceAnthropometric measurementsChronic malnutritionTreatment groupsChance findingStudy childrenResultsIn 2017Prevalence
2021
The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine
Sagara I, Zongo I, Cairns M, Yerbanga R, Mahamar A, Nikièma F, Tapily A, Sompougdou F, Diarra M, Zoungrana C, Issiaka D, Haro A, Sanogo K, Sienou A, Kaya M, Traore S, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B. The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine. Clinical Infectious Diseases 2021, 75: 613-622. PMID: 34894221, PMCID: PMC9464075, DOI: 10.1093/cid/ciab1017.Peer-Reviewed Original ResearchConceptsFirst booster doseDoses of RTSBooster doseAntibody responseSeasonal vaccinationPost-vaccination antibody titersAnti-circumsporozoite antibodiesBooster antibody responseDiminished antibody responsePrimary vaccination seriesSeasonal malaria chemopreventionSecond booster doseStrong antibody responseIncidence of malariaSubset of childrenEnzyme-linked immunosorbentVaccination seriesBooster dosesMalaria chemopreventionSevere malariaMalaria vaccineAntibody titersLower incidenceVaccinationAS01EHepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso
Compaoré Y, Zongo I, Somé A, Barry N, Nikiéma F, Kaboré T, Ouattara A, Kabré Z, Wermi K, Zongo M, Yerbanga R, Sagara I, Djimdé A, Ouédraogo J. Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso. Malaria Journal 2021, 20: 64. PMID: 33514368, PMCID: PMC7847156, DOI: 10.1186/s12936-021-03593-6.Peer-Reviewed Original ResearchConceptsHepatic adverse eventsArtemether-lumefantrineAL armAdverse eventsElevated ALTMalaria episodesUncomplicated malariaHepatic safetyDirect bilirubinPA armFirst-line anti-malarial drugHepatic safety profileUncomplicated malaria episodesElevated total bilirubinBobo-DioulassoLogistic regression modelsAnti-malarial drugsAlkaline phosphataseSubsequent malariaUnscheduled daysStudy armsSafety profileResultsA totalClinical trialsTotal bilirubin
2020
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study
Partnership A, Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, Roca-Feltrer A, Sanogo A, Johansson J, Tibenderana J, Abdoulaye R, Coulibaly P, Hubbard E, Jah H, Lama E, Razafindralambo L, Van Hulle S, Jagoe G, Tchouatieu A, Collins D, Gilmartin C, Tetteh G, Djibo Y, Ndiaye F, Kalleh M, Kandeh B, Audu B, Ntadom G, Kiba A, Savodogo Y, Boulotigam K, Sougoudi D, Guilavogui T, Keita M, Kone D, Jackou H, Ouba I, Ouedraogo E, Messan H, Jah F, Kaira M, Sano M, Traore M, Ngarnaye N, Elagbaje A, Halleux C, Merle C, Iessa N, Pal S, Sefiani H, Souleymani R, Laminou I, Doumagoum D, Kesseley H, Coldiron M, Grais R, Kana M, Ouedraogo J, Zongo I, Eloike T, Ogboi S, Achan J, Bojang K, Ceesay S, Dicko A, Djimde A, Sagara I, Diallo A, NdDiaye J, Loua K, Beshir K, Cairns M, Fernandez Y, Lal S, Mansukhani R, Muwanguzi J, Scott S, Snell P, Sutherland C, Tuta R, Milligan P. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. The Lancet 2020, 396: 1829-1840. PMID: 33278936, PMCID: PMC7718580, DOI: 10.1016/s0140-6736(20)32227-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAfrica, CentralAfrica, WesternAmodiaquineAntimalarialsCase-Control StudiesChemopreventionChildCost-Benefit AnalysisDrug CombinationsDrug ResistanceFeasibility StudiesHumansIncidenceMalariaProgram EvaluationPyrimethamineSafetySeasonsSulfadoxineSurveys and QuestionnairesYoung AdultConceptsSeasonal malaria chemopreventionCase-control studyHigh transmission periodMalaria chemopreventionObservational studyHealth-care staff timeHigh malaria transmission seasonDrug resistanceSerious adverse drug reactionsMalaria transmission seasonSerious adverse reactionsSevere skin reactionsCommunity health workersNational health management information systemAdverse drug reactionsCost-effectiveness ratioHealth Management Information SystemIndividual case safetyTarget populationMarker of resistanceSMC treatmentHospital admissionOutpatient clinicDrug reactionsSkin reactionsSeasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention
Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, Diarra M, Tapily A, Issiaka D, Sanogo K, Mahamar A, Sompougdou F, Yerbanga S, Thera I, Milligan P, Tinto H, Ofori-Anyinam O, Ouedraogo J, Greenwood B. Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01E vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention. BMJ Open 2020, 10: e035433. PMID: 32933955, PMCID: PMC7493088, DOI: 10.1136/bmjopen-2019-035433.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionClinical malariaTransmission seasonMalaria chemopreventionSeasonal vaccinationDoses of RTSWeekly active surveillancePlacebo-controlled trialPhase 3 trialMalaria transmission seasonPositive blood filmPrevalence of malariaSubsequent transmission seasonSubset of childrenCombination of vaccinationBooster doseModified intentionPrimary endpointControl vaccineFirst doseMalaria vaccineActive surveillanceCase detectionRabies vaccineHealth facilitiesEvaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali
Cairns M, Sagara I, Zongo I, Kuepfer I, Thera I, Nikiema F, Diarra M, Yerbanga S, Barry A, Tapily A, Coumare S, Milligan P, Tinto H, Ouédraogo J, Chandramohan D, Greenwood B, Djimde A, Dicko A. Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali. PLOS Medicine 2020, 17: e1003214. PMID: 32822362, PMCID: PMC7442230, DOI: 10.1371/journal.pmed.1003214.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionUncomplicated malariaTransmission seasonIntense seasonal malaria transmissionDay 28 PCRParasitological response rateUncomplicated clinical malariaPlacebo-controlled trialIncidence of hospitalisationSeasonal malaria transmissionIncidence rate ratiosBurden of malariaRapid diagnostic testsBougouni DistrictAsymptomatic malariaClinical malariaPlacebo groupStudy drugMalaria parasitaemiaAge range 3Parent trialAmodiaquine resistancePrevalence ratiosProtective efficacyDifferent distribution of malaria parasite in left and right extremities of vertebrate hosts translates into differences in parasite transmission
Pigeault R, Isaïa J, Yerbanga R, Dabiré K, Ouédraogo J, Cohuet A, Lefèvre T, Christe P. Different distribution of malaria parasite in left and right extremities of vertebrate hosts translates into differences in parasite transmission. Scientific Reports 2020, 10: 10183. PMID: 32576924, PMCID: PMC7311528, DOI: 10.1038/s41598-020-67180-6.Peer-Reviewed Original ResearchConceptsGametocyte densityMosquito infection ratesBlood samplesInfection rateNew malaria control strategiesMajor global causeMalaria control strategiesLow parasite burdenGametocyte burdenGametocyte carriersParasite transmissionPlasmodium infectionMosquito transmission potentialRight extremitiesTransmissible stagesParasite burdenMosquito transmissionMalaria parasitesPlasmodium sppGlobal causeTransmission potentialGametocytesVector-borne diseasesDiseaseExtremitiesA prebiotic-enhanced lipid-based nutrient supplement (LNSp) increases Bifidobacterium relative abundance and enhances short-chain fatty acid production in simulated colonic microbiota from undernourished infants
Toe L, Kerckhof F, De Bodt J, Morel F, Ouedraogo J, Kolsteren P, Van de Wiele T. A prebiotic-enhanced lipid-based nutrient supplement (LNSp) increases Bifidobacterium relative abundance and enhances short-chain fatty acid production in simulated colonic microbiota from undernourished infants. FEMS Microbiology Ecology 2020, 96: fiaa105. PMID: 32568403, DOI: 10.1093/femsec/fiaa105.Peer-Reviewed Original ResearchConceptsLipid-based nutrient supplementsBifidobacterium relative abundanceFatty acid productionAcid productionBranched-chain fatty acid productionNew therapeutic pathsLower gut microbiota diversityGut microbiota compositionPublic health problemHuman Intestinal Microbial EcosystemGut microbiota diversityIntestinal microbial ecosystemShort-chain fatty acid productionNutrient supplementsUndernourished infantsUndernourished childrenDynamic gut modelDeath proportionsMicrobiota compositionColonic microbiotaHealth problemsNutritional statusTherapeutic pathFecal microbiotaMicrobiota diversityEfficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
Zongo I, Compaoré Y, Nikiéma F, Zongo M, Barry N, Somé F, Kaboré N, Ouédraogo J. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan African Medical Journal 2020, 35: 68. PMID: 32537072, PMCID: PMC7250195, DOI: 10.11604/pamj.2020.35.68.20849.Peer-Reviewed Original ResearchConceptsFirst-line therapyLine therapyUncomplicated malariaPolymerase chain reactionTreatment efficacyEarly treatment failureGood tolerability profileFirst-line treatmentParasitological responsePrimary endpointTolerability profileArtemether-lumefantrineTreatment failureLine treatmentASAQ groupDay 28Better efficacyBurkina FasoTherapyMalariaEfficacyChain reactionCompletion ratesTreatmentDays